BEIGENE, LTD.
NASDAQ: ONC (BeOne Medicines Ltd.)
Kemas kini terakhir: 10 jam lalu350.13
-13.89 (-3.82%)
| Penutupan Terdahulu | 364.02 |
| Jumlah Dagangan | 408,917 |
| Harga / Pendapatan (P/E Ke hadapan) | 35.21 |
| Harga / Jualan (P/S) | 6.87 |
| Harga / Buku (P/B) | 7.98 |
| Julat 52 Minggu |
| Margin Keuntungan | -9.40% |
| Margin Operasi (TTM) | 0.99% |
| EPS Cair (TTM) | -3.69 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 48.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.49% |
| Nisbah Semasa (MRQ) | 1.96 |
| Aliran Tunai Operasi (OCF TTM) | 212.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -120.68 M |
| Pulangan Atas Aset (ROA TTM) | -3.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | BeOne Medicines Ltd. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.61 |
|
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company’s main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 17.31% |
| % Dimiliki oleh Institusi | 43.94% |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LEE CHAN HENRY | - | 365.94 | -1,115 | -408,023 |
| WANG XIAODONG | - | 367.00 | -31,028 | -11,387,276 |
| Jumlah Keseluruhan Kuantiti Bersih | -32,143 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -11,795,299 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 366.47 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LEE CHAN HENRY | Pegawai | 30 Sep 2026 | Jual automatik (-) | 1,115 | 365.94 | 408,023 |
| WANG XIAODONG | Pengarah | 28 Sep 2026 | Jual automatik (-) | 31,028 | 367.00 | 11,387,276 |
| WANG XIAODONG | Pengarah | 28 Sep 2026 | Pelaksanaan pilihan | 31,028 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |